Literature DB >> 16014680

Inhibition of c-kit tyrosine kinase by imatinib mesylate induces apoptosis in mast cells in rheumatoid synovia: a potential approach to the treatment of arthritis.

A Juurikivi1, C Sandler, K A Lindstedt, P T Kovanen, T Juutilainen, M J Leskinen, T Mäki, K K Eklund.   

Abstract

BACKGROUND: Mast cells have been implicated in the pathogenesis of arthritis, but elucidation of their precise role has been hampered by a lack of efficient and selective inhibitors of their function.
OBJECTIVE: To elucidate the role of mast cells in the pathogenesis of rheumatoid arthritis (RA) and to assess whether apoptosis of cultured and synovial tissue mast cells can be induced by inhibiting mast cell growth factor receptor, c-kit tyrosine kinase. METHODS AND
RESULTS: Double staining with tumour necrosis factor (TNF) alpha and tryptase antibodies showed the presence of TNFalpha positive mast cells in human rheumatoid synovial tissue. Selective activation of mast cells by anti-IgE resulted in production of TNFalpha in synovial tissue cultures. Inhibition of the c-kit tyrosine kinase with imatinib mesylate (1.0-10 micromol/l) induced profound apoptosis in cultured mast cells as judged by typical apoptotic morphology, increased number of apoptotic nucleosomes, and activation of caspases 8 and 9. Importantly, imatinib also induced apoptosis of mast cells in explant cultures of synovial tissue obtained from patients with RA as judged by a TUNEL assay. Inhibition of c-kit tyrosine kinase was accompanied by significant reduction of TNFalpha production in synovial tissue cultures.
CONCLUSION: Mast cells may have a role in the pathogenesis of RA, and inhibition of c-kit may be a new means of inhibiting mast cell activity and of abrogating the contribution of mast cells to synovial inflammation in RA.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16014680      PMCID: PMC1755598          DOI: 10.1136/ard.2004.029835

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  30 in total

1.  Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.

Authors:  H Joensuu; P J Roberts; M Sarlomo-Rikala; L C Andersson; P Tervahartiala; D Tuveson; S Silberman; R Capdeville; S Dimitrijevic; B Druker; G D Demetri
Journal:  N Engl J Med       Date:  2001-04-05       Impact factor: 91.245

Review 2.  The mast cell in inflammatory arthritis.

Authors:  David E Woolley
Journal:  N Engl J Med       Date:  2003-04-24       Impact factor: 91.245

3.  Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor.

Authors:  M C Heinrich; D J Griffith; B J Druker; C L Wait; K A Ott; A J Zigler
Journal:  Blood       Date:  2000-08-01       Impact factor: 22.113

4.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

Authors:  B J Druker; M Talpaz; D J Resta; B Peng; E Buchdunger; J M Ford; N B Lydon; H Kantarjian; R Capdeville; S Ohno-Jones; C L Sawyers
Journal:  N Engl J Med       Date:  2001-04-05       Impact factor: 91.245

5.  Efficacy of imatinib mesylate (STI571) treatment for a patient with rheumatoid arthritis developing chronic myelogenous leukemia.

Authors:  K Miyachi; A Ihara; R W Hankins; R Murai; S Maehiro; H Miyashita
Journal:  Clin Rheumatol       Date:  2003-10       Impact factor: 2.980

6.  Expression of stem cell factor (SCF) and SCF receptor (c-kit) in synovial membrane in arthritis: correlation with synovial mast cell hyperplasia and inflammation.

Authors:  A Ceponis; Y T Konttinen; M Takagi; J W Xu; T Sorsa; M Matucci-Cerinic; S Santavirta; H C Bankl; P Valent
Journal:  J Rheumatol       Date:  1998-12       Impact factor: 4.666

7.  Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms.

Authors:  Yael Zermati; Paulo De Sepulveda; Frederic Féger; Sebastion Létard; Joelle Kersual; Nathalie Castéran; Guy Gorochov; Michel Dy; Antoni Ribadeau Dumas; Karim Dorgham; Christophe Parizot; Yann Bieche; Michel Vidaud; Olivier Lortholary; Michel Arock; Olivier Hermine; Patrice Dubreuil
Journal:  Oncogene       Date:  2003-02-06       Impact factor: 9.867

8.  Mast cells: a cellular link between autoantibodies and inflammatory arthritis.

Authors:  David M Lee; Daniel S Friend; Michael F Gurish; Christophe Benoist; Diane Mathis; Michael B Brenner
Journal:  Science       Date:  2002-09-06       Impact factor: 47.728

9.  Treatment of rheumatoid arthritis with imatinib mesylate: clinical improvement in three refractory cases.

Authors:  Kari K Eklund; Heikki Joensuu
Journal:  Ann Med       Date:  2003       Impact factor: 4.709

10.  Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit.

Authors:  Cem Akin; Knut Brockow; Claudio D'Ambrosio; Arnold S Kirshenbaum; Yongsheng Ma; B Jack Longley; Dean D Metcalfe
Journal:  Exp Hematol       Date:  2003-08       Impact factor: 3.084

View more
  31 in total

Review 1.  Approaches for analyzing the roles of mast cells and their proteases in vivo.

Authors:  Stephen J Galli; Mindy Tsai; Thomas Marichal; Elena Tchougounova; Laurent L Reber; Gunnar Pejler
Journal:  Adv Immunol       Date:  2015-02-07       Impact factor: 3.543

Review 2.  Targeting innate immunity protein kinase signalling in inflammation.

Authors:  Matthias Gaestel; Alexey Kotlyarov; Michael Kracht
Journal:  Nat Rev Drug Discov       Date:  2009-06       Impact factor: 84.694

Review 3.  Tyrosine kinases as targets for the treatment of rheumatoid arthritis.

Authors:  Christina D'Aura Swanson; Ricardo T Paniagua; Tamsin M Lindstrom; William H Robinson
Journal:  Nat Rev Rheumatol       Date:  2009-06       Impact factor: 20.543

Review 4.  Immunomodulatory approaches to the management of chronic urticaria: an immune-mediated inflammatory disease.

Authors:  Clifton O Bingham
Journal:  Curr Allergy Asthma Rep       Date:  2008-07       Impact factor: 4.806

Review 5.  The immunological contribution to heterotopic ossification disorders.

Authors:  Michael R Convente; Haitao Wang; Robert J Pignolo; Frederick S Kaplan; Eileen M Shore
Journal:  Curr Osteoporos Rep       Date:  2015-04       Impact factor: 5.096

Review 6.  Signaling of c-kit in dendritic cells influences adaptive immunity.

Authors:  Prabir Ray; Nandini Krishnamoorthy; Timothy B Oriss; Anuradha Ray
Journal:  Ann N Y Acad Sci       Date:  2010-01       Impact factor: 5.691

7.  Platelet-derived growth factor and transforming growth factor beta synergistically potentiate inflammatory mediator synthesis by fibroblast-like synoviocytes.

Authors:  Sanna Rosengren; Maripat Corr; David L Boyle
Journal:  Arthritis Res Ther       Date:  2010-04-09       Impact factor: 5.156

8.  More about masitinib.

Authors:  Ulrich A Walker
Journal:  Arthritis Res Ther       Date:  2009-07-13       Impact factor: 5.156

Review 9.  Physiological and pathophysiological functions of intestinal mast cells.

Authors:  Stephan C Bischoff
Journal:  Semin Immunopathol       Date:  2009-06-17       Impact factor: 9.623

10.  Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study.

Authors:  Jacques Tebib; Xavier Mariette; Pierre Bourgeois; René-Marc Flipo; Philippe Gaudin; Xavier Le Loët; Paul Gineste; Laurent Guy; Colin D Mansfield; Alain Moussy; Patrice Dubreuil; Olivier Hermine; Jean Sibilia
Journal:  Arthritis Res Ther       Date:  2009-06-23       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.